A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

Phase 2 Completed 20 enrolled BioCryst Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency.

Evaluation	Drug	Modality	Dose	Route
Subject	Ulodesine	Small molecule	5 mg	Oral
Subject	Ulodesine	Small molecule	10 mg	Oral